• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一例伴有基因扩增的老年难治性B细胞急性淋巴细胞白血病的重复谱系转换:病例报告及文献综述

Repeated Lineage Switches in an Elderly Case of Refractory B-Cell Acute Lymphoblastic Leukemia With Gene Amplification: A Case Report and Literature Review.

作者信息

Takeda Reina, Yokoyama Kazuaki, Fukuyama Tomofusa, Kawamata Toyotaka, Ito Mika, Yusa Nozomi, Kasajima Rika, Shimizu Eigo, Ohno Nobuhiro, Uchimaru Kaoru, Yamaguchi Rui, Imoto Seiya, Miyano Satoru, Tojo Arinobu

机构信息

Department of Hematology/Oncology, Research Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Division of Cellular Therapy, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

出版信息

Front Oncol. 2022 Mar 23;12:799982. doi: 10.3389/fonc.2022.799982. eCollection 2022.

DOI:10.3389/fonc.2022.799982
PMID:35402256
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8983914/
Abstract

Lineage switches in acute leukemia occur rarely, and the underlying mechanisms are poorly understood. Herein, we report the case of an elderly patient with leukemia in which the leukemia started as B-cell acute lymphoblastic leukemia (B-ALL) and later changed to B- and T-cell mixed phenotype acute leukemia (MPAL) and acute myeloid leukemia (AML) during consecutive induction chemotherapy treatments. A 65-year-old woman was initially diagnosed with Philadelphia chromosome-negative B-ALL primarily expressing TdT/CD34/HLA-DR; more than 20% of the blasts were positive for CD19/CD20/cytoplasmic CD79a/cytoplasmic CD22/CD13/CD71.The blasts were negative for T-lineage markers and myeloperoxidase (MPO). Induction chemotherapy with the standard regimen for B-ALL resulted in primary induction failure. After the second induction chemotherapy regimen, the blasts were found to be B/T bi-phenotypic with additional expression of cytoplasmic CD3. A single course of clofarabine (the fourth induction chemotherapy regimen) dramatically reduced lymphoid marker levels. However, the myeloid markers (e.g., MPO) eventually showed positivity and the leukemia completely changed its lineage to AML. Despite subsequent intensive chemotherapy regimens designed for AML, the patient's leukemia was uncontrollable and a new monoblastic population emerged. The patient died approximately 8 months after the initial diagnosis without experiencing stable remission. Several cytogenetic and genetic features were commonly identified in the initial diagnostic B-ALL and in the following AML, suggesting that this case should be classified as lineage switching leukemia rather than multiple simultaneous cancers (i.e., B-ALL and AML, or primary B-ALL and therapy-related myeloid neoplasm). A complex karyotype was persistently observed with a hemi-allelic loss of chromosome 17 (the location of the tumor suppressor gene). As the leukemia progressed, the karyotype became more complex, with the additional abnormalities. Sequential target sequencing revealed an increased variant allele frequency of mutation. Fluorescent hybridization (FISH) revealed an increased number of () genes, both before and after lineage conversion. In contrast, FISH revealed negativity for rearrangements, which are well-known abnormalities associated with lineage switching leukemia and MPAL. To our best knowledge, this is the first reported case of acute leukemia presenting with lineage ambiguity and gene amplification.

摘要

急性白血病中的谱系转换很少发生,其潜在机制也知之甚少。在此,我们报告一例老年白血病患者的病例,该患者的白血病最初为B细胞急性淋巴细胞白血病(B-ALL),在连续的诱导化疗过程中,后来转变为B和T细胞混合表型急性白血病(MPAL)和急性髓系白血病(AML)。一名65岁女性最初被诊断为费城染色体阴性B-ALL,主要表达TdT/CD34/HLA-DR;超过20%的原始细胞CD19/CD20/细胞质CD79a/细胞质CD22/CD13/CD71呈阳性。原始细胞T系标志物和髓过氧化物酶(MPO)呈阴性。采用B-ALL标准方案进行诱导化疗导致初次诱导失败。在第二个诱导化疗方案后,发现原始细胞为B/T双表型,伴有细胞质CD3的额外表达。单疗程氯法拉滨(第四个诱导化疗方案)显著降低了淋巴系标志物水平。然而,髓系标志物(如MPO)最终呈阳性,白血病谱系完全转变为AML。尽管随后针对AML设计了强化化疗方案,但患者的白血病仍无法控制,并且出现了新的单核细胞群体。患者在初次诊断后约8个月死亡,未经历稳定缓解。在初始诊断的B-ALL和随后的AML中共同发现了几种细胞遗传学和遗传学特征,表明该病例应归类为谱系转换白血病,而非多种同时发生的癌症(即B-ALL和AML,或原发性B-ALL和治疗相关髓系肿瘤)。持续观察到复杂核型,伴有17号染色体半等位基因缺失(肿瘤抑制基因所在位置)。随着白血病进展,核型变得更加复杂,出现了额外的异常。序列靶向测序显示突变的变异等位基因频率增加。荧光原位杂交(FISH)显示在谱系转换前后, 基因数量均增加。相比之下,FISH显示 重排为阴性, 重排是与谱系转换白血病和MPAL相关的众所周知的异常。据我们所知,这是首例报告的表现为谱系不明确和 基因扩增的急性白血病病例。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/80c9/8983914/3c63c212a7fa/fonc-12-799982-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/80c9/8983914/757eaa0db1ed/fonc-12-799982-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/80c9/8983914/0c149f682b97/fonc-12-799982-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/80c9/8983914/3c63c212a7fa/fonc-12-799982-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/80c9/8983914/757eaa0db1ed/fonc-12-799982-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/80c9/8983914/0c149f682b97/fonc-12-799982-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/80c9/8983914/3c63c212a7fa/fonc-12-799982-g003.jpg

相似文献

1
Repeated Lineage Switches in an Elderly Case of Refractory B-Cell Acute Lymphoblastic Leukemia With Gene Amplification: A Case Report and Literature Review.一例伴有基因扩增的老年难治性B细胞急性淋巴细胞白血病的重复谱系转换:病例报告及文献综述
Front Oncol. 2022 Mar 23;12:799982. doi: 10.3389/fonc.2022.799982. eCollection 2022.
2
Therapy-related myeloid neoplasm in an 18-year-old boy with B-lymphoblastic leukemia.一名患有B淋巴细胞白血病的18岁男孩的治疗相关髓系肿瘤
Exp Mol Pathol. 2017 Dec;103(3):263-266. doi: 10.1016/j.yexmp.2017.11.007. Epub 2017 Nov 16.
3
Clinicopathological differences between T-lymphoblastic leukemia/lymphoma, early T-precursor lymphoblastic leukemia/lymphoma, and mixed-phenotype acute leukemia with T lineage: An analysis of 41 adult cases.T 淋巴母细胞白血病/淋巴瘤、早期 T 前体细胞淋巴母细胞白血病/淋巴瘤和伴有 T 系的混合表型急性白血病的临床病理差异:41 例成人病例分析。
Hum Pathol. 2024 Aug;150:78-85. doi: 10.1016/j.humpath.2024.06.016. Epub 2024 Jun 28.
4
Acute leukemias with complex karyotype show a similarly poor outcome independent of mixed, myeloid or lymphoblastic immunophenotype: A study from the Bone Marrow Pathology Group.具有复杂核型的急性白血病,不论免疫表型为混合性、髓性或淋巴母细胞性,其预后均相似不良:来自骨髓病理学组的一项研究。
Leuk Res. 2023 Jul;130:107309. doi: 10.1016/j.leukres.2023.107309. Epub 2023 May 10.
5
Double and single mixed-lineage leukemia-rearranged subclones in pediatric acute myeloid leukemia: a case report.儿童急性髓系白血病中双和单混合谱系白血病重排亚克隆:一例报告。
J Med Case Rep. 2021 May 7;15(1):228. doi: 10.1186/s13256-021-02841-2.
6
Genomic Landscape of Mixed-Phenotype Acute Leukemia.混合表型急性白血病的基因组景观。
Int J Mol Sci. 2022 Sep 24;23(19):11259. doi: 10.3390/ijms231911259.
7
Phenotypic conversion from t(8;21) acute myeloid leukemia to MLL gene rearrangement-positive acute lymphoblastic leukemia.
Hematopathol Mol Hematol. 1998;11(3-4):185-92.
8
[Extramedullary onset of mixed phenotype acute leukemia with MLL gene rearrangement].[伴有MLL基因重排的混合表型急性白血病髓外发病]
Rinsho Ketsueki. 2013 Mar;54(3):290-4.
9
Role of CD71 in acute leukemia- An immunophenotypic marker for erythroid lineage or proliferation?CD71在急性白血病中的作用——红系谱系或增殖的免疫表型标志物?
Indian J Pathol Microbiol. 2019 Jul-Sep;62(3):418-422. doi: 10.4103/IJPM.IJPM_604_18.
10
Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase II.先前接受过靶向DNA拓扑异构酶II药物治疗的患者中,治疗相关急性髓系白血病的MLL基因重排情况。
Blood. 1993 Dec 15;82(12):3705-11.

引用本文的文献

1
Lineage Switch of Adult B-Cell Acute Lymphoblastic Leukaemia to Acute Myeloid Leukaemia Following B-Cell-Directed Therapy.B细胞定向治疗后成人B细胞急性淋巴细胞白血病向急性髓系白血病的谱系转换
Eur J Case Rep Intern Med. 2025 Aug 27;12(9):005724. doi: 10.12890/2025_005724. eCollection 2025.
2
A shadow in the treatment of acute leukemia: lineage switch.急性白血病治疗中的一个难题:谱系转换。
Blood Sci. 2025 Mar 20;7(2):e00220. doi: 10.1097/BS9.0000000000000220. eCollection 2025 Jun.
3
Myeloid lineage switch in rearranged acute lymphoblastic leukemia treated with lymphoid lineagedirected therapies.

本文引用的文献

1
Infant leukaemia - faithful models, cell of origin and the niche.婴儿白血病——忠实的模型、起源细胞和龛位。
Dis Model Mech. 2021 Oct 1;14(10). doi: 10.1242/dmm.049189. Epub 2021 Oct 29.
2
Does lineage plasticity enable escape from CAR-T cell therapy? Lessons from MLL-r leukemia.谱系可塑性是否能使白血病逃避 CAR-T 细胞治疗?来自 MLL-r 白血病的教训。
Exp Hematol. 2021 Aug;100:1-11. doi: 10.1016/j.exphem.2021.07.002. Epub 2021 Jul 21.
3
Mutations in Acute Myeloid Leukemia: Still a Daunting Challenge?急性髓系白血病中的突变:仍是一项艰巨的挑战?
采用淋巴系定向疗法治疗的重排型急性淋巴细胞白血病中的髓系谱系转换
Haematologica. 2024 Jan 1;109(1):293-297. doi: 10.3324/haematol.2023.283705.
Front Oncol. 2021 Feb 8;10:610820. doi: 10.3389/fonc.2020.610820. eCollection 2020.
4
The MLL/SET family and haematopoiesis.MLL/SET 家族与造血。
Biochim Biophys Acta Gene Regul Mech. 2020 Aug;1863(8):194579. doi: 10.1016/j.bbagrm.2020.194579. Epub 2020 May 7.
5
Human erythroleukemia genetics and transcriptomes identify master transcription factors as functional disease drivers.人类红细胞白血病遗传学和转录组学确定了主要转录因子作为功能性疾病驱动因子。
Blood. 2020 Aug 6;136(6):698-714. doi: 10.1182/blood.2019003062.
6
Optimal therapeutic strategies for mixed phenotype acute leukemia.混合表型急性白血病的最佳治疗策略。
Curr Opin Hematol. 2020 Mar;27(2):95-102. doi: 10.1097/MOH.0000000000000570.
7
An Unusually Short Latent Period of Therapy-Related Myeloid Neoplasm Harboring a Rare MLL-EP300 Rearrangement: Case Report and Literature Review.一例罕见MLL-EP300重排的治疗相关髓系肿瘤潜伏期异常短暂:病例报告及文献综述
Case Rep Hematol. 2019 Oct 2;2019:4532434. doi: 10.1155/2019/4532434. eCollection 2019.
8
Ontogenic Changes in Hematopoietic Hierarchy Determine Pediatric Specificity and Disease Phenotype in Fusion Oncogene-Driven Myeloid Leukemia.在融合癌基因驱动的髓系白血病中,造血层次的个体发生变化决定了儿科的特异性和疾病表型。
Cancer Discov. 2019 Dec;9(12):1736-1753. doi: 10.1158/2159-8290.CD-18-1463. Epub 2019 Oct 29.
9
A dominant-negative effect drives selection of missense mutations in myeloid malignancies.显性负效应驱动髓系恶性肿瘤中错义突变的选择。
Science. 2019 Aug 9;365(6453):599-604. doi: 10.1126/science.aax3649.
10
Breakage-Fusion-Bridge Events Trigger Complex Genome Rearrangements and Amplifications in Developmentally Arrested T Cell Lymphomas.断裂-融合-桥循环事件在发育停滞的 T 细胞淋巴瘤中引发复杂的基因组重排和扩增。
Cell Rep. 2019 Jun 4;27(10):2847-2858.e4. doi: 10.1016/j.celrep.2019.05.014.